Diabetes & Alzheimer’s: New Link Explained
- Individuals with type 2 diabetes face a greater risk of developing Alzheimer's disease and other cognitive impairments.
- The study focused on beta-amyloids, key components of brain plaques found in Alzheimer's patients.
- However, shortly after the glucose infusion, the control group experienced a sharp decline in beta-amyloid levels and a rise in the amyloid-degrading enzyme.
type 2 diabetes could considerably heighten your risk of Alzheimer’s disease, according to groundbreaking research. news Directory 3 reports on a new study indicating a potential link: impaired protein clearance. Scientists observed how individuals with diabetes struggled to remove beta-amyloids, proteins associated with Alzheimer’s brain plaques, after a glucose infusion, unlike control groups. This highlights the critical need for diabetes prevention and proactive blood sugar management to protect cognitive health. Failing to effectively process these proteins could contribute to their dangerous buildup. Early detection and understanding are crucial. Learn about the study’s findings and the importance of understanding this growing concern. Discover what’s next …
Type 2 Diabetes May Heighten Alzheimer’s Disease Risk
Updated June 26, 2025
Individuals with type 2 diabetes face a greater risk of developing Alzheimer’s disease and other cognitive impairments. Research from Umeå University in Sweden suggests this increased risk may stem from a reduced ability to eliminate a specific protein linked to the onset of Alzheimer’s.
The study focused on beta-amyloids, key components of brain plaques found in Alzheimer’s patients. Researchers analyzed blood concentrations of beta-amyloids Aβ1-40 and Aβ1-42, along with an amyloid-degrading enzyme, in both a type 2 diabetes group and a control group. Both groups underwent glucose infusions to induce high blood sugar levels,followed by repeated blood sampling.
Initially, both groups showed similar beta-amyloid levels. However, shortly after the glucose infusion, the control group experienced a sharp decline in beta-amyloid levels and a rise in the amyloid-degrading enzyme. In contrast, the type 2 diabetes group showed no important changes in either beta-amyloid levels or enzyme activity.
These findings suggest that people with type 2 diabetes may not process beta-amyloid as effectively as those without the condition. This could lead to a buildup of the protein in the brain, potentially increasing the risk of cognitive diseases like alzheimer’s. The study included 10 participants with type 2 diabetes and 11 in the control group, all aged 66-72.
“The results might potentially be critically important for further research into possible treatments to counteract the risk of people with type 2 diabetes being affected by Alzheimer’s,” said Olov Rolandsson, senior professor at umeå University and the study’s lead author.
What’s next
Rolandsson emphasized the need for further research to validate these initial findings. He also stressed the importance of preventing type 2 diabetes and managing blood sugar levels in those already diagnosed, potentially mitigating the risk of Alzheimer’s disease and cognitive decline.